Pulmonary Hypertension

March 31, 2016April 4, 2016

Stanford Children’s Health Pediatric Cardiologist to Be Recognized by American Thoracic Society for Her Work

At the American Thoracic Society’s annual meeting in San Francisco in May, Dr. Marlene Rabinovitch of the Lucile Packard Children’s Hospital Stanford will give the J. Burns Amberson Lecture. The lecture recognizes “a career ... Read more

March 24, 2016March 24, 2016

Actelion’s PAH Therapy, Uptravi (selexipag), Approved for Use in Australia and New Zealand

News, Pulmonary Hypertension

Actelion, Ltd., recently announced the approval of Uptravi (selexipag) by the Therapeutic Goods Administration (TGA) of Australia and the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) for the treatment ... Read more

March 23, 2016February 1, 2019

In PAH Patients, Low Activity Levels May Lead to Fatigue, Little Energy, Study Shows

News, Pulmonary Hypertension

More than 90 percent of patients with pulmonary arterial hypertension (PAH) report fatigue, but it has not been known if fatigue has an impact on physical activity in these patients. ... Read more

March 4, 2016March 4, 2016

Actelion Emphasizes Commitment to Patients on Rare Disease Day

News, Pulmonary Hypertension

The theme of Rare Disease Day 2016, “Patient Voice — Join us in making the voice of rare diseases heard,” was a major cause for Switzerland-based Actelion, a leader in the field ... Read more

February 24, 2016February 24, 2016

Athlete with CTED but Without Pulmonary Hypertension Undergoes Successful Surgery to Remove Fibrotic Clots

News, Pulmonary Hypertension

A recent study discussed a case report of a 43-year-old male athlete with progressive exercise limitation after experiencing a pulmonary embolism (blockage of a pulmonary blood vessel), but without signs ... Read more

February 22, 2016February 22, 2016

Macitentan Shown to Prevent, Treat Pulmonary Hypertension in Transgenic Mice Model

News, Pulmonary Hypertension

A collaborative research project between the University College London, England, and Actelion Pharmaceuticals Ltd. in Switzerland found that the drug macitentan, an endothelin receptor antagonist approved for treatment of pulmonary ... Read more

February 18, 2016February 18, 2016

Likely PAH Prognosis May Be Evident in Tissue Phase Mapping of Left Ventricle

News, Pulmonary Hypertension

A tissue phase mapping study reported that left ventricular (LV) function is abnormal in patients with pulmonary arterial hypertension (PAH) and is related to clinical outcomes. The new insights could help ... Read more

February 16, 2016February 18, 2016

New Referrals for PH Patients in UK Increases by 21 Percent in Five Years

News, Pulmonary Hypertension

According to a national audit in the United Kingdom published by the Health and Social Care Information Centre (HSCIC), the number of new referrals for pulmonary hypertension (PH) patients increased ... Read more

February 16, 2016February 18, 2016

PAH Treatment Long-Term Trial Results of Bellerophon’s INOpulse Are Encouraging

News, Pulmonary Hypertension

Bellerophon Therapeutics recently announced the results from the final analysis (Part 2) of its Phase 2 long-term extension clinical trial on iNO/INOpulse drug-device combination product for the treatment of patients with ... Read more

February 15, 2016February 18, 2016

In Certain People with PAH, Researchers Identify Markers for Lower Mortality Rates

News, Pulmonary Hypertension, Scleroderma

A new study demonstrated that specific antibodies could be markers for decreased mortality in people with connective tissue disease and systemic sclerosis associated with pulmonary arterial hypertension (PAH). The report in ... Read more